CITF Research Results

CITF Research Results2023-10-27T10:53:53-04:00

Antibody wane being observed yet breakthrough infections rare: Latest Canadian Blood Services report

In their latest report, Canadian Blood Services reveals that 97% of blood donors sampled in September had evidence of antibodies against SARS-CoV-2 acquired through immunization with at least one vaccine dose and/or a past infection. This number is largely driven by vaccination as infection-acquired seroprevalence remained low in September - at 4.4% - despite the ongoing fourth wave. September results show evidence of antibody [...]

December 6, 2021|General population studies|

Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF). Principal investigator Dr. Brian Grunau, Assistant Professor in UBC’s Department of Emergency Medicine and Scientist at [...]

December 1, 2021|Healthcare workers, Media Releases|

How adolescents with inflammatory bowel disease treated with immunosuppressive drugs respond to COVID-19 vaccination

In a letter published in Gut, Dr. Kevan Jacobson, Dr. Pascal Lavoie and collaborators from the University of British Columbia report modestly lower antibody levels in adolescents, aged 12 to 17 years, with inflammatory bowel disease (IBD) who are on the anti-TNF-a anti-inflammatory therapy infliximab in combination with other immunosuppressive drugs or given as monotherapy, after a first dose of Pfizer-BioNTech’s Comirnaty vaccine.

November 30, 2021|Pediatrics|

COVID-19 vaccine coverage among pregnant individuals in Ontario

In their third report, CITF-funded researcher Dr. Deshayne Fell and her team at the Better Outcomes Registry & Network (BORN) in Ontario found that 58.7% of people who were pregnant in September 2021 had received at least one dose of a COVID-19 vaccine before or during pregnancy. Since pregnant individuals are considered a high-risk population for COVID-19 complications based on higher rates of hospitalization, ICU admission, and death, compared [...]

November 19, 2021|Geographic & priority populations|
Go to Top